Patricia Gaule
About Patricia Gaule
Patricia Gaule is a Principal Scientist at Bristol Myers Squibb in New Jersey, with a background in cancer research and molecular biology.
Company
Patricia Gaule currently works at Bristol Myers Squibb as a Principal Scientist in New Jersey, United States. In her role, she collaborates with interdisciplinary teams to advance translational pathology projects. Her work has contributed to the development of a new therapeutic approach that is currently in clinical trials for cancer treatment.
Title
Patricia Gaule holds the position of Principal Scientist. She previously worked as an Associate Research Scientist at Yale University from 2017 to 2022, and as a Post-Doctoral Researcher at Yale School of Medicine from 2015 to 2022.
Education and Expertise
Patricia Gaule received her Doctor of Philosophy (PhD) in Molecular Biology from Dublin City University, where she also received a prestigious fellowship from the Irish Research Council. Additionally, she holds a Bachelor of Science (BS) and a Bachelor's degree in Biomedical Sciences from University College Cork and the Cork Institute of Technology, respectively. Her academic background primarily focuses on biomedical sciences and molecular biology.
Background
Patricia Gaule has an extensive career spanning various research and medical institutions. She initially worked as a Medical Scientist at Waterford Regional Hospital for one year, then as a Helpdesk Attendant at Aras na Mac Leinn, UCC. Her research career developed significantly at Yale University, culminating in a role as Associate Research Scientist. Now at Bristol Myers Squibb, she focuses on cancer research and therapeutic development.
Achievements
Patricia Gaule has published multiple research papers in high-impact journals, primarily focusing on cancer research and molecular biology. She presented her findings at international conferences, including the American Association for Cancer Research (AACR) Annual Meeting. She also developed a novel antibody-based assay that significantly improved the detection of specific cancer biomarkers.